Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection

doi:10.3748/wjg.v24.i12.1361

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 12

This Article

(289)

(414)

(0)

(19)

(6)

(7982)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Randomized Clinical Trial

World J Gastroenterol. Mar 28, 2018; 24(12): 1361-1372
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1361

Table 1 Baseline demographics and disease characteristics n (%)¹

Characteristic	Immediate treatment, n = 155²	Placebo-deferred treatment, n = 52	Overall, n = 207²
Age, median (range) years	49 (18-73)	49 (23-69)	49 (18-73)
< 65 yr	142 (92)	45 (87)	187 (90)
≥ 65 yr	13 (8)	7 (14)	20 (10)
Male	61 (39)	23 (44)	84 (41)
Race
Asian	132 (85)	45 (87)	177 (86)
White	23 (15)	7 (14)	30 (15)
Country
Mainland China	119 (77)	42 (81)	161 (78)
Russia	23 (15)	7 (14)	30 (15)
South Korea	13 (8)	3 (6)	16 (8)
HCV RNA, median (range) log₁₀ IU/mL	6.78 (3.1-7.6)	6.86 (5.6-7.6)	6.79 (3.1-7.6)
≥ 6 million IU/mL	79 (51)	31 (60)	110 (53)
IL28B genotype
CC	107 (69)	34 (65)	141 (68)
CT	43 (28)	17 (33)	60 (29)
TT	5 (3)	1 (2)	6 (3)
Cirrhosis	19 (12)	7 (14)	26 (13)

¹Unless otherwise stated;

²Includes one patient from mainland China who was subsequently reclassified as having HCV genotype 1a infection by phylogenetic analysis of the HCV NS5A sequence. HCV: Hepatitis C virus.

Full Size Table

Citation: Wei L, Wang FS, Zhang MX, Jia JD, Yakovlev AA, Xie W, Burnevich E, Niu JQ, Jung YJ, Jiang XJ, Xu M, Chen XY, Xie Q, Li J, Hou JL, Tang H, Dou XG, Gandhi Y, Hu WH, McPhee F, Noviello S, Treitel M, Mo L, Deng J. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. World J Gastroenterol 2018; 24(12): 1361-1372
URL: https://www.wjgnet.com/1007-9327/full/v24/i12/1361.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i12.1361

Wei L, Wang FS, Zhang MX, Jia JD, Yakovlev AA, Xie W, Burnevich E, Niu JQ, Jung YJ, Jiang XJ, Xu M, Chen XY, Xie Q, Li J, Hou JL, Tang H, Dou XG, Gandhi Y, Hu WH, McPhee F, Noviello S, Treitel M, Mo L, Deng J. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. World J Gastroenterol 2018; 24(12): 1361-1372 [PMID: 29599611 DOI: 10.3748/wjg.v24.i12.1361]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.